INO Stock Overview
A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Inovio Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.87 |
| 52 Week High | US$14.75 |
| 52 Week Low | US$1.74 |
| Beta | 0.84 |
| 1 Month Change | -13.02% |
| 3 Month Change | -67.02% |
| 1 Year Change | -77.74% |
| 3 Year Change | -96.28% |
| 5 Year Change | -95.47% |
| Change since IPO | -99.74% |
Recent News & Updates
Recent updates
Here's Why We're Watching Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation
Aug 11
Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates
May 15Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates
May 13Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?
Oct 23Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug
Oct 13Inovio Pharmaceuticals: Long On Promise, Short On Results
Sep 27Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M
Aug 09Inovio: After All These Years
Jul 19Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022
Apr 15Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?
Mar 21Inovio Undervalued On Potential 2022 Catalyst
Jan 26Shareholder Returns
| INO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.5% | -3.6% | -1.2% |
| 1Y | -77.7% | -8.4% | 23.2% |
Return vs Industry: INO underperformed the US Biotechs industry which returned -8.4% over the past year.
Return vs Market: INO underperformed the US Market which returned 23.2% over the past year.
Price Volatility
| INO volatility | |
|---|---|
| INO Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 19.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: INO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INO's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 127 | Jacqueline Shea | www.inovio.com |
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial.
Inovio Pharmaceuticals, Inc. Fundamentals Summary
| INO fundamental statistics | |
|---|---|
| Market cap | US$48.81m |
| Earnings (TTM) | -US$112.88m |
| Revenue (TTM) | US$203.41k |
239.9x
P/S Ratio-0.4x
P/E RatioIs INO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INO income statement (TTM) | |
|---|---|
| Revenue | US$203.41k |
| Cost of Revenue | US$81.97m |
| Gross Profit | -US$81.77m |
| Other Expenses | US$31.11m |
| Earnings | -US$112.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.32 |
| Gross Margin | -40,198.50% |
| Net Profit Margin | -55,491.09% |
| Debt/Equity Ratio | 0% |
How did INO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/15 01:53 |
| End of Day Share Price | 2025/01/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Inovio Pharmaceuticals, Inc. is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aydin Huseynov | Benchmark Company |
| Geoffrey Meacham | BofA Global Research |
| Jonathan Aschoff | Brean Capital |